Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.70 +3.45%
Revenue Growth %: -33.6%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: -33.6%
Financial Fact:
OPERATING LOSS: -6.65M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.16). Revenue for the quarter came in at $24.84 million versus the consensus estimate of $10.22 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Datadog shares drop on weak Q4 revenue outlook
- Intel shares fall as competitor reports record results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
